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Background: Type 2 diabetes mellitus (T2DM) is a major global health problem. An estimated 
20%–50% of diabetic subjects in Canada are currently undiagnosed, and around 20%–30% 
have already developed complications. Screening for high blood glucose levels can identify 
people with prediabetic conditions and permit introduction of timely and effective prevention. 
This study examines the benefit of screening for impaired fasting glucose (IFG) and T2DM. 
If intervention is introduced at this prediabetic stage, it can be most effective in delaying the 
onset and complications of T2DM.
Methods: Using a Markov model simulation, we compare the cost-effectiveness of   screening 
for prediabetes (IFG) and T2DM with the strategy of no screening. An initial cohort of 
  normoglycemic, prediabetic, or undiagnosed diabetic adults with one or more T2DM risk   factors 
was used to model the strategies mentioned over a 10-year period. Subjects without known 
prediabetes or diabetes are screened every 3 years and persons with prediabetes were tested 
for diabetes on an annual basis. The model weighs the increase in quality-adjusted life-years 
(QALYs) associated with early detection of prediabetes and earlier diagnosis of T2DM due to 
lifestyle intervention and early treatment in asymptomatic subjects.
Results: Costs for each QALY gained were $2281 for conventional screening compared with 
$2890 for no screening. Thus, in this base-case analysis, conventional screening with a frequency 
of once every 3 years was favored over no screening. Furthermore, conventional screening was 
more favorable compared with no screening over a wide range of willingness-to-pay   thresholds. 
Changing the frequency of screening did not affect the overall results. Screening persons 
without diabetes or prediabetes on an annual basis had small effects on the cost-effectiveness 
ratios. Screening with a frequency of once every 5 years resulted in the lowest cost per QALY 
($2117). Lack of screening costs the health care system $4812 more than the cost of screening 
once every 5 years.
Conclusion: The increased cost per QALY of not screening is due to the costs of complications 
caused downstream of T2DM. By ensuring that IFG screening occurs every 3 years for those 
without prediabetes and every year for those with prediabetes, the health and financial benefits 
related to T2DM are improved in Canada.
Keywords: type 2 diabetes, Markov model, economic analysis, cost-effectiveness, quality-
adjusted life-years
Introduction
Type 2 diabetes mellitus (T2DM) is a major health problem, not only in North America 
but globally. According to the World Health Organization, 343 million people worldwide 
have diabetes, 90% of whom have T2DM.1 This has prompted health care workers 
to recognize diabetes as a significant public health problem. In Canada, there are 
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2.9 million people with diabetes.2 An estimated 20%–50% 
of diabetic subjects in Canada are currently undiagnosed, and 
around 20%–30% have already developed complications.3 
Unless treated, the disease may lead to serious complications 
including chronic kidney disease, neuropathy, retinopathy, 
and cardiovascular diseases, leading to major economic 
impacts.1 The prevalence of T2DM is also expected to rise 
further due to the increased rates of risk factors associated 
with the disease, such as obesity, physical inactivity, and 
consumption of dietary fat.
Screening for high blood glucose levels can identify 
people with prediabetic conditions and permit introduction 
of timely and effective prevention. Although targeted 
screening for T2DM is widely performed among different 
patient and “at-risk” groups in Canada, currently there is 
no systematic screening policy for the disease. According 
to the recommendations of the Canadian Task Force on 
  Preventive Health Care, screening involves only individuals 
who are asymptomatic and is most effective if conducted 
twice.4 Those who exhibit symptoms or signs of T2DM, and 
those who have potential disease-related complications are 
  recommended to undergo diagnostic testing.4 According to 
the Canadian Diabetes Association, a fasting plasma glucose 
is recommended to be performed every 3 years in individuals 
40 years of age and older.5
One approach for T2DM screening would be to focus 
screening on the disease only. Although this approach will 
allow for early diagnosis and treatment, it will not permit 
possible delay in the disease onset. However, an alternative 
approach is to screen for T2DM as well as prediabetic status 
via impaired glucose tolerance or impaired fasting glucose. 
If intervention is introduced at the prediabetic stage, it can 
be most effective in delaying the onset and complications of 
T2DM. Intervention strategies may encompass both lifestyle 
and nutritional factors, and are known to reduce the risk 
of T2DM complications markedly.6
Numerous mathematical simulation studies have been 
employed to determine the effectiveness of screening for 
T2DM or prediabetic status.7–11 Previous models of screening 
for T2DM alone have generally assessed the impact of 
a single screening and early treatment of cardiovascular 
events, whereas other models included microvascular 
events, such as retinopathy.3 Overall, these models produced 
favorable economic outcomes for T2DM screening, although 
cost-effectiveness varied according to the age groups, 
the environmental risk factors associated with the disease, 
and the population targeted.3 To our knowledge, no study has 
reported cost-effectiveness of T2DM screening for the entire 
Canadian population. According to the Canadian Diabetes 
Association, testing for T2DM in prediabetic subjects is likely 
to achieve an overall saving in health care costs.5 Therefore, 
the present study was undertaken in an attempt to assess 
the health benefits and health care cost reduction associated 
with early screening strategies for prediabetic conditions and 
T2DM in Canada, using a Markov model simulation.
Materials and methods
Model structure
Using a Markov model simulation, we compared the cost-
effectiveness of no screening with conventional screening 
for prediabetes (impaired fasting glucose) and T2DM. The 
model was developed using TreeAge software (TreeAge 
Inc, Williamstown, MA) and consisted of a Markov 
state-transition model, as shown in Figure 1 and a Markov 
simulation model, as shown in Figure 2. The model tracks 
a cohort of individuals who are at risk for T2DM, with at 
least one risk factor from those shown in Table 1. Each 
adult individual may be normoglycemic, prediabetic, or 
have undiagnosed diabetes. Therefore, each person entering 
the model may start the first cycle in any of the three states, 
ie, normal glucose, impaired fasting glucose undetected, or 
T2DM undetected. The prevalence of undetected impaired 
fasting glucose and undiagnosed T2DM in the population 
is used to estimate how many individuals start in each of 
the three states.12 Patients who have already been identified 
as having T2DM are excluded from the screening process. 
IFG
(undetected)
Normal
glucose
state
IFG
(screen
detected)
T2D
(screen
detected)
T2D
(complications)
T2D
(undetected)
Death
Figure 1 Markov state-transition model with the seven proposed health states and 
possible transitions to be performed once for each screening method. 
Notes: Whether type 2 diabetes and impaired fasting glucose are diagnosed or 
undiagnosed determines if the patients receive relevant treatments or interventions 
and whether associated costs and utilities are applied for each time interval. Dotted 
circles represent starting states.
Abbreviation: IFG, impaired fasting glucose; T2D, type 2 diabetes mellitus.
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Patients can be identified through either a screening program 
or symptom-based case finding.
A patient’s health is characterized by distinct health 
states, and the natural history is summarized by the possible 
transitions between these states. Health states are defined 
based on the following components: the health condition 
(ie, alive or dead), blood glucose level (normal, diabetic or 
prediabetic), and whether the patients’ status is known (as a 
result of either screening or symptom-based case finding) or 
unknown. These components result in the following seven 
states: normal glucose level, impaired fasting glucose states 
(undetected impaired fasting glucose and detected); T2DM 
states (undetected, screen detected, and diagnosed with 
  complications); and death. The transitions between these 
seven states are illustrated in Figure 1. Based on the diagnosis 
of T2DM and impaired fasting glucose, the patients would 
receive relevant treatment or intervention regimen.
Health-state transition assumptions
Transition between the health states described above occur 
on a one-year cycle. Subjects who start at normal glucose 
state may stay in this state or progress to either impaired 
fasting glucose screen-detected or screen-undetected during 
the year ahead. If they progress to one of the two impaired 
fasting glucose conditions, they will move to the corre-
sponding state in the next cycle based on their test result. 
For example, a true positive test places the individual in 
the state of “impaired fasting glucose detected”. However, 
a false negative test places the patient in “impaired fast-
ing glucose undetected state” because they have already 
developed impaired fasting glucose. If they do not progress 
to impaired fasting glucose, and their test result is negative 
(true   negative), they remain in the normal glucose state, 
otherwise they will be falsely labeled as “impaired fasting 
glucose detected” and will move to the “impaired fasting 
glucose detected” state in the next cycle and receive relevant 
intervention/treatment. Those who start at “impaired fasting 
glucose undetected” may progress to T2DM. If their test 
result is positive, they are truly   diagnosed with T2DM and 
move to “T2DM detected” state in the next cycle. If their 
result is negative, it is a false negative condition because they 
have developed T2DM and move to “T2DM undetected”. 
Those who do not progress to T2DM will move to “impaired 
glucose tolerance detected” state or remain at the state of 
“impaired fasting glucose undetected” according to their test 
result (see Figure 1 for transition among other states).
Model assumptions
A one-year cycle over a time period of 10 years was used 
for the simulation. The model allows for annual screening 
for prediabetes and diabetes, as well as screening performed 
within longer intervals. For the base-case analysis, subjects 
without known prediabetes or diabetes are screened every 
3 years and persons with prediabetes are tested for diabetes 
on an annual basis. The Canadian Diabetes Association 
recommends a screening frequency of 3 years for subjects 
without known prediabetes or diabetes, and a higher fre-
quency for persons with higher risk of diabetes.5 Moving 
from the normal glucose state to T2DM in the model occurs 
through impaired fasting glucose states. Subsequently, indi-
viduals with prediabetes reside in this state for at least one 
year before they develop T2DM. Indeed, developing T2DM 
within one year of having normal glucose level is relatively 
rare. There is no transition in this model from T2DM 
back to impaired fasting glucose or from impaired fasting 
glucose to a normal glucose state. This is clinically sound 
because once an individual has a diagnosis of T2DM, even 
if the glucose levels improve, it can still be clinically defined 
as having the disease. Also, once an individual has impaired 
fasting glucose, even if the fasting glucose decreases, the 
future risk of T2DM is probably more similar to that of 
an individual with impaired fasting glucose rather than an 
individual who has always had normal fasting glucose levels. 
Another assumption employed here proposes that once an 
individual develops T2DM (undetected) or is diagnosed 
with the disease by screening (T2DM detected), he or she 
will spend at least one cycle in the respective states before 
developing T2DM complications.
Table 1 Risk factors for type 2 diabetes1
Risk factor
Age 40 years
First-degree relative with type 2 diabetes
Member of high-risk population (eg, people of Aboriginal, Hispanic,  
South Asian, Asian, or African descent)
History of IGT or IFG
Presence of complications associated with diabetes
Vascular disease (coronary, cerebrovascular, or peripheral)
History of gestational diabetes mellitus
Hypertension
Dyslipidemia
Overweight
Abdominal obesity
Polycystic ovary syndrome
Acanthosis nigricans
Schizophrenia
Note: 1Risk factors were generated by the Canadian Diabetes Association 2008 Clinical 
Practice Guidelines for the Prevention and Management of Diabetes in Canada.5 
Abbreviations: IGT, impaired glucose tolerance; IFG, impaired fasting glucose.
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Model input
The inputs into the Markov model consisted of the preva-
lence of undiagnosed T2DM and impaired fasting glucose, 
probabilities of moving from one state to the next,2,12,13 
sensitivity and specificity of tests,12–15 and the effectiveness 
of lifestyle modification programs for people with impaired 
glucose   tolerance in the Diabetes Prevention Program.14 In 
comparisons with placebo, lifestyle and metformin inter-
ventions reduce the incidence of T2DM by 58% and 31%, 
respectively. The lifestyle modification program has goals 
of 7% weight loss and 150 minutes of weekly physical 
activity.8,14
The standard quality-of-life values (evaluated from the 
EQ-5D) were used to populate quality-adjusted life-years 
(QALYs) for each of the health states previously men-
tioned. Costs such as those for screening and confirmatory 
diagnostic tests were taken from the report prepared for the 
Ontario   Ministry of Health and Long-term Care and applied 
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Figure 2 Markov model simulation for the impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada. 
Notes: Two Markov models are run, one for a no screening strategy and the other for a prediabetes and diabetes screening strategy. Appropriate costs for treatment 
or lifestyle modification programs are applied for those detected by screening as IFG or T2DM, and those who are clinically diagnosed with T2DM because of diabetic 
complications. Conventional screening is denoted by “Yes”. 
Abbreviations: IFG, impaired fasting glucose; TP, true positive test result; Tn, true negative; Fn, false negative; FP, false positive; T2DM, type 2 diabetes mellitus.
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Table 2 Base-case input values for the Markov model1
Parameter Base-case value
Demographic variables
Age at start of screening program (years) 40
Prevalence of undiagnosed T2DM 5% (1.4%–50%)3,12
Prevalence of undetected IFG 12%3
Transition rates
normal to IFG (per 100 person-years) 1.66 (0.08)15,18
IFG to T2DM (per 100 person-years) 1.96 (0.25)19
Test efficiency
We assumed a sensitivity and specificity  
of almost 100% for two consecutive tests  
for T2DM and for IFG (for T2DM, sensitivity 
83%, specificity 91%; for IFG only,  
sensitivity 53%, specificity 63%)12,13,20,21
Costs $ (per person)2
Screening test 30
Diagnostic test 45
Average annual direct medical costs  
  (for diabetes with complications)
5687 (5371–6343)16
Average annual direct medical costs  
  (for diabetes without complications)
221016
Average annual lifestyle modification costs 50014,22,23
Utilities
Utility of undetected T2DM 0.79 (0.02)3
Utility of screen detected T2DM 0.79 (0.02)3
Utility of T2DM with complications 0.77 (0.03)24
Note:  1Costs  were  reported  in  Canadian  dollars  from  year  2010  and  were 
standardized by inflation indices.2  Adjusted according to the laboratory and physician 
fee schedules.16
Abbreviations: T2DM, type 2 diabetes mellitus; IFG, impaired fasting glucose.
to be lower, we used the costs estimated from the inten-
sively treated patients.16 For those with clinically diagnosed 
diabetes, we used the reported costs for the conventionally 
treated patients.16 All costs were reported in Canadian dollars 
from year 2010 and were standardized by inflation indices 
(Table 2).
Results and discussion
Several studies have evaluated the cost effectiveness of 
screening for T2DM.7,8,12,25,26 However, few studies have 
compared the cost benefits of screening in both prediabetic 
and diabetic subjects3,27 and, to our knowledge, no study 
has targeted the Canadian population. The United Kingdom 
Prospective Diabetes study model was adopted to develop a 
cost-benefit analysis of diabetes management in Ontario.28 
In the present study of cost-effectiveness of screening for 
impaired fasting glucose and T2DM, we observed the cost 
and health benefits of early detection of prediabetes and 
previously unrecognized T2DM. Our results demonstrate 
that screening is most favorable for those over 40 years 
of age (or in subjects with at least one risk factor) when 
performed on prediabetic subjects every 5 years. For this 
outcome to be substantiated, it is critical that screening be 
followed by intervention protocols targeted at delaying the 
onset of T2DM.
The Markov model was applied to assess a 10-year/  lifetime 
progression of T2DM, costs, QALYs, and   incremental cost-
effectiveness ratios. We adopted a health system perspective 
that considers only direct medical costs, discounting costs and 
QALYs at 3% per year. The outcomes for the model over a 
10-year period, with discounting of both costs and benefits at 
3% a year and testing persons with prediabetic conditions for 
T2DM annually, is shown in Table 3. The cost for each QALY 
gained is $2281 for conventional screening, compared with 
Table 3 Sensitivity analysis and variation in frequency of screening
Screening  
strategy
Cost 
($)
Incremental  
cost ($)
Effect  
(QALYs)
Incremental  
effectiveness 
(QALYs)
Cost/effect 
($/QALYs)
Incremental C/E 
(ICER)
Once every 3 years (basecase)
  Yes1 16,800 7.387 2281 16,800
  no 20,500 3600 7.081 -0.306 2890 (Dominated)
Once every 5 years
  Yes1 15,653 7.40 2116
  no 20,466 4812 7.08 -0.31 2890 (Dominated)
Once every year
  Yes1 17,500 7.379 2367
  no 20,500 3000 7.081 -0.298 2890 (Dominated)
Note: 1“Yes” represents screening at stated frequency for normal subjects and once every year for subjects with prediabetes. 
Abbreviations: QALYs, quality-adjusted life-years; C/E, cost/effectiveness; ICER, incremental cost-effectiveness ratio.
for all Canadians.16 Costs of pharmacological interventions 
for impaired glucose tolerance were based on metformin 
250 mg three times per day, the standard dose used by most 
intervention studies.16,17 For the costs of pharmacological 
interventions in people with diagnosed T2DM, the aver-
age annual costs of antidiabetic treatment for Canada were 
used.16 Furthermore, for subjects with T2DM detected at 
screening, in whom we would expect costs of complications 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
95
Screening and early detection of diabetesClinicoEconomics and Outcomes Research 2012:4
21000
20000
19000
18000
17000
16000
15000
7 7.1 7.2 7.3
Effectiveness ratio
C
o
s
t
 
(
C
D
N
$
)
7.4 7.5
Figure 3 Cost-effectiveness comparison between conventional screening for type 2 
diabetes mellitus and no screening. 
Notes:  Conventional  screening  strategy  (square)  is  compared  with  no  screening 
(triangle). The dominated strategy is highlighted by a circle (ie, conventional screening).
$2890 for no screening. These base-case results are shown 
on the cost-effectiveness plane in Figure 3. Therefore, in 
the base-case, the conventional screening strategy of using 
a screening frequency of once every 3 years dominated the 
no screening strategy.
A sensitivity analysis was conducted on the frequency of 
screening (Figure 3) to understand the most effective screen-
ing interval period. Screening persons without known diabe-
tes or prediabetes on an annual basis had small effects on the 
cost-effectiveness ratios, and screening with the frequency 
of once every 5 years resulted in the lowest cost per QALY, 
ie, $2117. It costs the health care system $4812 more to not 
screen patients rather than screen every 5 years (Table 3). 
This is due to the costs of complications caused downstream 
of diabetes. The cost-effectiveness acceptability curve 
(Figure 4) illustrates the probability of cost-effectiveness of 
each strategy over a range of willingness-to-pay thresholds 
and indicates the overall level of uncertainty in the model. 
Conventional screening tends to be favorable compared 
with no screening over a wide range of willingness-to-pay 
thresholds. Changing the frequency of screening did not 
affect the overall results.
The results support conventional screening every 3 years, 
with a wide variation in the cost of screening for prediabetes 
and diabetes. It should be noted that the model only takes 
into account the health care costs from the perspective of the 
health care system. There are further sensitivity data points 
that can be examined in the model. Prevalence rates for 
  diabetes could be graphed from 1% to 100% to understand 
the threshold of screening frequency and the health and 
financial implications over time for decision-makers. Also, 
a more concise average of provincial health care costs could 
be incorporated into the study to model better the implications 
for each province. Another area for further research would be 
to expand the chosen time horizon of 10 years for the model. 
This could be expanded to a lifetime horizon to simulate better 
the slow natural progression of the disease, as was carried out 
by Schaufler and Wolff   29 who developed a similar model over 
a lifetime horizon for the German health care system.
In conclusion, our study demonstrates that early screening 
for prediabetes and T2DM to prevent or delay onset of the 
disease has positive public health and economic impacts in 
Canada. Through prevention and early treatment of T2DM, 
the time spent in the more severe and costly states can be 
markedly reduced. Therefore, by ensuring impaired fasting 
glucose screening occurs every 3 years for those without 
prediabetes and every year for those with prediabetes, 
the health and financial benefits related to T2DM can be 
improved in Canada.
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